EIDX Eidos Therapeutics Inc.
NewsSee all news
-
BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures
AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular Hospitalization (25.5%)
-
Eidos Therapeutics Reports Third Quarter 2019 Financial Results and Business Update
SAN FRANCISCO, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (NASDAQ:EIDX), a subsidiary of BridgeBio Pharma, Inc. (BridgeBio) (NASDAQ:BBIO), today reported its financial results for the third
-
BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics
Agreement Not Reached Between BridgeBio Pharma and Special Committee of Eidos Therapeutics Independent Directors; BridgeBio No Longer Pursuing Acquisition BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage
-
Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy at the AHA 2019 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation
SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (NASDAQ:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in transthyretin
-
Eidos Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
SAN FRANCISCO, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (NASDAQ:EIDX) today announced that management will present at the 2019 Cantor Global Healthcare Conference on Thursday, October 3rd at
Drug Information
Drug catalyst information is displayed when you hover over / tap on the stage bar graph.
Latest News
-
BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures
AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular Hospitalization (25.5%)
-
Eidos Therapeutics Reports Third Quarter 2019 Financial Results and Business Update
SAN FRANCISCO, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (NASDAQ:EIDX), a subsidiary of BridgeBio Pharma, Inc. (BridgeBio) (NASDAQ:BBIO), today reported its financial results for the third
-
BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics
Agreement Not Reached Between BridgeBio Pharma and Special Committee of Eidos Therapeutics Independent Directors; BridgeBio No Longer Pursuing Acquisition BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage
-
Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy at the AHA 2019 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation
SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (NASDAQ:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in transthyretin
-
Eidos Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
SAN FRANCISCO, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (NASDAQ:EIDX) today announced that management will present at the 2019 Cantor Global Healthcare Conference on Thursday, October 3rd at
-
Eidos Therapeutics Special Committee Rejects Proposal from BridgeBio Pharma to Acquire Shares
Advises Stockholders Take No Action at this Time Eidos Therapeutics, Inc. (NASDAQ:EIDX) ("Eidos") announced today that the Special Committee of its Board of Directors (the "Special Committee") unanimously rejected the
-
Kaskela Law LLC Announces Shareholder Investigation of Eidos Therapeutics, Inc. and Encourages Investors to Contact the Firm – EIDX
PHILADELPHIA, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Kaskela Law LLC is investigating Eidos Therapeutics, Inc. ("Eidos") (NASDAQ:EIDX) on behalf of the company's shareholders. The investigation seeks to determine whether